Artwork

Content provided by Clarivate. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clarivate or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Utilizing pluripotent stem cells in cell therapy

25:55
 
Share
 

Manage episode 279172561 series 2813433
Content provided by Clarivate. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clarivate or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Brian Culley, CEO of Lineage Cell Therapeutics. Brian and Mike discuss the company’s cell therapy program, utilizing pluripotent stem cells, initially targeting dry age-related macular degeneration, acute spinal cord injuries, and non-small cell lung cancer. Brian shares about the status of their Phase 1/2a clinical trials, and how COVID-19 has affected the company’s operations.

Hosted on Acast. See acast.com/privacy for more information.

  continue reading

48 episodes

Artwork
iconShare
 
Manage episode 279172561 series 2813433
Content provided by Clarivate. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clarivate or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Brian Culley, CEO of Lineage Cell Therapeutics. Brian and Mike discuss the company’s cell therapy program, utilizing pluripotent stem cells, initially targeting dry age-related macular degeneration, acute spinal cord injuries, and non-small cell lung cancer. Brian shares about the status of their Phase 1/2a clinical trials, and how COVID-19 has affected the company’s operations.

Hosted on Acast. See acast.com/privacy for more information.

  continue reading

48 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide